Cargando…
Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy
The purpose of this work was to develop an end-to-end patient-specific quality assurance (QA) technique for spot-scanned proton therapy that is more sensitive and efficient than traditional approaches. The patient-specific methodology relies on independently verifying the accuracy of the delivered p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375645/ https://www.ncbi.nlm.nih.gov/pubmed/30763390 http://dx.doi.org/10.1371/journal.pone.0212412 |
_version_ | 1783395402486120448 |
---|---|
author | Johnson, J. E. Beltran, C. Wan Chan Tseung, H. Mundy, D. W. Kruse, J. J. Whitaker, T. J. Herman, M. G. Furutani, K. M. |
author_facet | Johnson, J. E. Beltran, C. Wan Chan Tseung, H. Mundy, D. W. Kruse, J. J. Whitaker, T. J. Herman, M. G. Furutani, K. M. |
author_sort | Johnson, J. E. |
collection | PubMed |
description | The purpose of this work was to develop an end-to-end patient-specific quality assurance (QA) technique for spot-scanned proton therapy that is more sensitive and efficient than traditional approaches. The patient-specific methodology relies on independently verifying the accuracy of the delivered proton fluence and the dose calculation in the heterogeneous patient volume. A Monte Carlo dose calculation engine, which was developed in-house, recalculates a planned dose distribution on the patient CT data set to verify the dose distribution represented by the treatment planning system. The plan is then delivered in a pre-treatment setting and logs of spot position and dose monitors, which are integrated into the treatment nozzle, are recorded. A computational routine compares the delivery log to the DICOM spot map used by the Monte Carlo calculation to ensure that the delivered parameters at the machine match the calculated plan. Measurements of dose planes using independent detector arrays, which historically are the standard approach to patient-specific QA, are not performed for every patient. The nozzle-integrated detectors are rigorously validated using independent detectors in regular QA intervals. The measured data are compared to the expected delivery patterns. The dose monitor reading deviations are reported in a histogram, while the spot position discrepancies are plotted vs. spot number to facilitate independent analysis of both random and systematic deviations. Action thresholds are linked to accuracy of the commissioned delivery system. Even when plan delivery is acceptable, the Monte Carlo second check system has identified dose calculation issues which would not have been illuminated using traditional, phantom-based measurement techniques. The efficiency and sensitivity of our patient-specific QA program has been improved by implementing a procedure which independently verifies patient dose calculation accuracy and plan delivery fidelity. Such an approach to QA requires holistic integration and maintenance of patient-specific and patient-independent QA. |
format | Online Article Text |
id | pubmed-6375645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63756452019-03-01 Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy Johnson, J. E. Beltran, C. Wan Chan Tseung, H. Mundy, D. W. Kruse, J. J. Whitaker, T. J. Herman, M. G. Furutani, K. M. PLoS One Research Article The purpose of this work was to develop an end-to-end patient-specific quality assurance (QA) technique for spot-scanned proton therapy that is more sensitive and efficient than traditional approaches. The patient-specific methodology relies on independently verifying the accuracy of the delivered proton fluence and the dose calculation in the heterogeneous patient volume. A Monte Carlo dose calculation engine, which was developed in-house, recalculates a planned dose distribution on the patient CT data set to verify the dose distribution represented by the treatment planning system. The plan is then delivered in a pre-treatment setting and logs of spot position and dose monitors, which are integrated into the treatment nozzle, are recorded. A computational routine compares the delivery log to the DICOM spot map used by the Monte Carlo calculation to ensure that the delivered parameters at the machine match the calculated plan. Measurements of dose planes using independent detector arrays, which historically are the standard approach to patient-specific QA, are not performed for every patient. The nozzle-integrated detectors are rigorously validated using independent detectors in regular QA intervals. The measured data are compared to the expected delivery patterns. The dose monitor reading deviations are reported in a histogram, while the spot position discrepancies are plotted vs. spot number to facilitate independent analysis of both random and systematic deviations. Action thresholds are linked to accuracy of the commissioned delivery system. Even when plan delivery is acceptable, the Monte Carlo second check system has identified dose calculation issues which would not have been illuminated using traditional, phantom-based measurement techniques. The efficiency and sensitivity of our patient-specific QA program has been improved by implementing a procedure which independently verifies patient dose calculation accuracy and plan delivery fidelity. Such an approach to QA requires holistic integration and maintenance of patient-specific and patient-independent QA. Public Library of Science 2019-02-14 /pmc/articles/PMC6375645/ /pubmed/30763390 http://dx.doi.org/10.1371/journal.pone.0212412 Text en © 2019 Johnson et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Johnson, J. E. Beltran, C. Wan Chan Tseung, H. Mundy, D. W. Kruse, J. J. Whitaker, T. J. Herman, M. G. Furutani, K. M. Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
title | Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
title_full | Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
title_fullStr | Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
title_full_unstemmed | Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
title_short | Highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
title_sort | highly efficient and sensitive patient-specific quality assurance for spot-scanned proton therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375645/ https://www.ncbi.nlm.nih.gov/pubmed/30763390 http://dx.doi.org/10.1371/journal.pone.0212412 |
work_keys_str_mv | AT johnsonje highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT beltranc highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT wanchantseungh highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT mundydw highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT krusejj highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT whitakertj highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT hermanmg highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy AT furutanikm highlyefficientandsensitivepatientspecificqualityassuranceforspotscannedprotontherapy |